My, my, my. What a long thread with so many different posters.......all of whom are one and the same person......the Bozo who's been spamming this board for years by employing many of his different monikers to make it appear a "conversation" is taking place among many different people.
I laugh at the many-monikered Bozo.
ha ha ha ha ha ha
There are 2 posibilities. 1. Kelsey may be on the way out or 2. Geron is going for early approval on GRN1005 under the new FDA regulations that take effect January 1, 2013 for unmet medical needs fast track and aproval post phase 2. If Geron is taking the accelerated path for GRN1005 then they would need someone in this position for GRN1005 to run the required future trials and over see the developement of the regulatory required production facility needed for regulatory approval. Everyone should remember that none of Gerons current trials are blinded so the company is aware of what is going on it is we the shareholders who are blinded from the trial.
Jonah, Geron did not get "blown out of the water." For Heavens sake, this was a patent interference action. Geron still has its patent but at this stage it looks to be not as broad as they might contend.
Mr. K provided us links and gave us his opinions. I too, after reading the stuff, did not think much differently than Mr. K. Perhaps so did others on this board. Didn't you too think the same way? If so, we all mislead others who did not bother to reviw the stuff!!
I do not think the position is simply for GRN1005, although it will be the first responsibility to start with. The following qualification requirements seem important to me:
"- Good understanding of clinical oncology and the drug development process, including drug supply, preclinical development and commercialization
......take initiatives and smart risks
- Articulate with strong verbal presentation skills
- Good business judgment and excellent organizational skills"
These are requirements of somebody like Okarma for the forthcoming oncology plans that include therapeutic as well as clinical development and apparently manufacturing or at least coordination with subcinrtract manufacurer(s). There is no body at present in the company that fits these qualifiications, especially the clinical/manufactuiringside! Mr. K's title to this post thus is certainly misleading!!
To me, it surely looks like the company is gearing up to go full steam ahead to manufacturing and marketing of Imetelstat and, later, GRN1005. It doesn't look like it's looking for a merger with a large pharma to do that. Stem-cell divestiture is certain and full-steam oncology expansion is very much in the cards. I will just say, the company is implying through this, "stay tuned".